OXODIPINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H21NO6
Molecular Weight	359.3731
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC3=C2OCO3)C(=O)OC

InChI

InChIKey=MSOAVHHAZCMHDI-UHFFFAOYSA-N

InChI=1S/C19H21NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8,16,20H,5,9H2,1-4H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8323416 | https://adisinsight.springer.com/drugs/800000193

Oxodipine is a dihydropyridine calcium channel blocker that has been developed by IQB as an antihypertensive agent. Experiments on dogs have shown that oxodipine exerted a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties. in addition, in Europe, the drug was involved in phase III clinical trials in and in phase II for the treatment of Hypertension. Besides, oxodipine was studied for the treatment of ischaemic heart disorders. However, these studied were discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes.	1998-09-11	9788778
Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs.	1993-01-01	8323416

Patents

Name

Type

Language

Oxodipine [WHO-DD]

Preferred Name

English

OXODIPINE

Official Name

English

oxodipine [INN]

Common Name

English

ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(2,3-(METHYLENEDIOXY)PHENYL)-3,5-PYRIDINEDICARBOXYLATE

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID50869063